Inhibition of S/G2 phase CDK4 reduces mitotic fidelity

被引:28
作者
Burgess, A
Wigan, M
Giles, N
DePinto, W
Gillespie, P
Stevens, F
Gabrielli, B [1 ]
机构
[1] Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia
[2] Hoffmann La Roche Inc, Discovery Oncol, Nutley, NJ 07110 USA
[3] Hoffmann La Roche Inc, Discovery Chem, Nutley, NJ 07110 USA
关键词
D O I
10.1074/jbc.M512714200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclin-dependent kinase 4 (CDK4)/cyclin D has a key role in regulating progression through late G(1) into S phase of the cell cycle. CDK4-cyclin D complexes then persist through the latter phases of the cell cycle, although little is known about their potential roles. We have developed small molecule inhibitors that are highly selective for CDK4 and have used these to define a role for CDK4-cyclin D in G(2) phase. The addition of the CDK4 inhibitor or small interfering RNA knockdown of cyclin D3, the cyclin D partner, delayed progression through G(2) phase and mitosis. The G(2) phase delay was independent of ATM/ATR and p38 MAPK but associated with elevated Wee1. The mitotic delay was because of failure of chromosomes to migrate to the metaphase plate. However, cells eventually exited mitosis, with a resultant increase in cells with multiple or micronuclei. Inhibiting CDK4 delayed the expression of the chromosomal passenger proteins survivin and borealin, although this was unlikely to account for the mitotic phenotype. These data provide evidence for a novel function for CDK4-cyclin D3 activity in S and G(2) phase that is critical for G(2)/M progression and the fidelity of mitosis.
引用
收藏
页码:9987 / 9995
页数:9
相关论文
共 35 条
[1]  
BATES S, 1994, ONCOGENE, V9, P1633
[2]   p38 and Chk1 kinases:: different conductors for the G2/M checkpoint symphony [J].
Bulavin, DV ;
Amundson, SA ;
Fornace, AJ .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2002, 12 (01) :92-97
[3]  
Burgess AJ, 2001, MOL PHARMACOL, V60, P828
[4]   Survivin is required for stable checkpoint activation in taxol-treated HeLa cells [J].
Carvalho, A ;
Carmena, M ;
Sambade, C ;
Earnshaw, WC ;
Wheatley, SP .
JOURNAL OF CELL SCIENCE, 2003, 116 (14) :2987-2998
[5]  
Castellano M, 1997, CANCER RES, V57, P4868
[6]   Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC [J].
Chan, GKT ;
Jablonski, SA ;
Sudakin, V ;
Hittle, JC ;
Yen, TJ .
JOURNAL OF CELL BIOLOGY, 1999, 146 (05) :941-954
[7]   Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores [J].
Ditchfield, C ;
Johnson, VL ;
Tighe, A ;
Ellston, R ;
Haworth, C ;
Johnson, T ;
Mortlock, A ;
Keen, N ;
Taylor, SS .
JOURNAL OF CELL BIOLOGY, 2003, 161 (02) :267-280
[8]   Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb [J].
Ezhevsky, SA ;
Nagahara, H ;
VoceroAkbani, AM ;
Gius, DR ;
Wei, MC ;
Dowdy, SF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10699-10704
[9]   A small molecule-kinase interaction map for clinical kinase inhibitors [J].
Fabian, MA ;
Biggs, WH ;
Treiber, DK ;
Atteridge, CE ;
Azimioara, MD ;
Benedetti, MG ;
Carter, TA ;
Ciceri, P ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Galvin, M ;
Gerlach, JL ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Insko, MA ;
Lai, AG ;
Lélias, JM ;
Mehta, SA ;
Milanov, ZV ;
Velasco, AM ;
Wodicka, LM ;
Patel, HK ;
Zarrinkar, PP ;
Lockhart, DJ .
NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336
[10]  
Gabrielli BG, 1996, J CELL SCI, V109, P1081